NCT02717858View on ClinicalTrials.gov

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 16, 2016

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

liraglutide

Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.

DRUG

placebo

Injected s.c./subcutaneously (under the skin) once daily.

Trial Locations (1)

2900

Novo Nordisk Investigational Site, Hellerup

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY